Clinical Trial

Adjunctive Ivermectin Mass Drug Administration for Malaria Control

Brief description

This is a cluster-randomized placebo-controlled clinical trial to evaluate the additive benefit of Ivermectin (IVM) (or Placebo) mass drug administration (MDA) to dihydroartemisinin-piperaquine (DP) MDA for malaria control in a moderate to low malaria-endemic setting as an adjunctive strategy to existing programmatic malaria control measures. The regime of DP and IVM will target both human reservoirs of Plasmodium falciparum and the Anopheles gambiae vector respectively, with the aim of interrupting transmission. The trial will be conducted on the Bijagos Archipelago, where islands (clusters) will be randomised to receive seasonal DP and IVM or DP and Placebo MDA. The primary outcome will be the prevalence of infection with Plasmodium falciparum in all age groups detected by nucleic acid amplification testing during the peak malaria transmission season after two years of intervention.

Detailed Description

The objectives of this trial are 1. To evaluate the impact of adjunctive IVM to DP MDA on malaria transmission in communities with high ITN coverage. 2. To evaluate the impact of IVM MDA on An. gambiae population density and age-structure. 3. To evaluate the impact of IVM MDA on the prevalence of co-endemic IVM-susceptible Neglected Tropical Diseases (lymphatic filariasis, soil transmitted helminths and scabies) 4. To evaluate acceptability, feasibility and access to MDA as a strategy for malaria control and to identify the most acceptable way of achieving and sustaining high coverage MDA with IVM and DP. This cluster-randomized placebo-controlled trial has two arms. A total of 24 clusters will be randomly assigned to receive DP + IVM MDA or DP+ Placebo MDA using computer-generated random numbers. To mitigate against contamination effects, the majority of clusters will be separate islands and will be separated by distances greater than 2km. On the two islands that are divided (each into two clusters), a buffer zone of 2km between each cluster will be ensured. The total population of the archipelago is 24,000. The investigators will ensure balance between trial arms with respect to population size, baseline Plasmodium falciparum prevalence and access to health care. All clusters will receive the standard programmatic malaria control interventions implemented by the National Malaria Control Programme which includes insecticide-treated nets (ITN), intermittent preventative treatment in pregnancy (IPTp), seasonal malarial chemoprophylaxis (SMC) for children aged 3-59 months and case diagnosis and treatment (CDT) with Artemether-lumefantrine.


  •   Lymphatic Filariasis
  •   Hook Worm
  •   Malaria,Falciparum
  •   Neglected Tropical Diseases
  •   Strongyloidiasis
  •   Soil Transmitted Helminths
  •   Scabies

Sponsored By

London School of Hygiene and Tropical Medicine

Unique Study ID


Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Bandim Health Project
Bissau, Bissau Codex, Guinea-Bissau
Distance from Current Trial is 0 miles

Amabélia Rodrigues, MD, PhD

University of Southern Denmark
1004, Bissau, SAB, Guinea-Bissau
Distance from Current Trial is 0 miles

No Investigator Listed

Bandim Health Project
Bissau, Guinea-Bissau
Distance from Current Trial is 0 miles
View All